Fig. 3: Lestaurtinib inhibits JAK/STAT signaling. | npj Precision Oncology

Fig. 3: Lestaurtinib inhibits JAK/STAT signaling.

From: Lestaurtinib’s antineoplastic activity converges on JAK/STAT signaling to inhibit treatment naïve and therapy resistant forms ovarian cancer

Fig. 3

Volcano plots depicting differentially expressed genes in (a) MDAH and (b) OVSAHO cells, where blue indicates downregulated and red indicates upregulated genes ( | fold change | ≥ 1.5, p < 0.05 and FDR < 0.1). The number of of significantly regulated genes are indicated. Bubble plots depicting significantly regulated pathways following lestaurtinib treatment of (c) MDAH and (d) OVSAHO cells as identified by Ingenuity Pathway Analysis. Bubble blots depicting predicted upstream regulators that likely contribute to lestaurtinib mediated differential gene expression in (e) MDAH and (f) OVSAHO cells. g PCA plot generated from RNAseq results of MDAH and OVSAHO cells treated with vehicle and lestaurtinib. h Venn diagram depicting the overlap of lestaurtinib regulated genes in MDAH and OVSAHO cells. i Line graph showing concordance/discordance of the 161 commonly regulated by lestauritnib in both MDAH and OVSAHO cell lines. Abbreviations: Lest lestaurtinib, Veh vehicle. Pathways and regulators with p < 0.05 and |z-score | > 2 are shown.

Back to article page